CK5, CK5/6, and double-stains CK7/CK5 and p53/CK5 discriminate in situ vs invasive urothelial cancer in the prostate

American Journal of Clinical Pathology

Volumn 138, Issue 2, 2012, Pages 190-197

  Fichtenbaum, Eric J ^a   Marsh, William L ^a   Zynger, Debra L ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

CK5; Immunohistochemistry; Prostate; Staging; Urothelial carcinoma

Indexed keywords

ACID PHOSPHATASE; ANDROGEN RECEPTOR; ANTIGEN; CD141 ANTIGEN; CD44S ANTIGEN; CYTOKERATIN 20; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; HIGH MOLECULAR WEIGHT KERATIN; KERATIN; LAMININ; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; PROTEIN P63; UNCLASSIFIED DRUG;

ARTICLE; BASAL CELL; CANCER INVASION; CANCER STAGING; CARCINOMA IN SITU; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; CYSTECTOMY; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; STAINING; UROGENITAL TRACT TUMOR;

EID: 84865428546     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP5ZC4GQVNWTYR     Document Type: Article

References (32)

1. American Cancer Society. Cancer Facts and Figures 2010 Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-026238.pdf. Accessed May 18, 2012.
2. Edge SB, Byrd DR, Compton CC, et al. eds. AJCC Cancer Staging Manual 7th ed. New York, NY: Springer; 2010:chap 45.
3. Sawczuk I, Tannenbaum M, Olsson CA, et al. Primary transitional cell carcinoma of prostatic periurethral ducts. Urology. 1985;25:339-343. (Pubitemid 16078178)
4. Schellhammer PF, Bean MA, Whitmore WF Jr. Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis. J Urol 1977;118:399-403. (Pubitemid 8200219)
5. Grabstald H. Prostatic biopsy in selected patients with carcinoma in situ of the bladder: preliminary report. J Urol. 1984;132:1117-1118. (Pubitemid 15213869)
6. Mahadevia PS, Koss LG, Tar IJ. Prostatic involvement in bladder cancer: prostate mapping in 20 cystoprostatectomy specimens. Cancer. 1986;58:2096-2102. (Pubitemid 16008789)
7. Wood DP Jr., Montie JE, Pontes JE, et al. Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. J Urol. 1989;141:346-349. (Pubitemid 19061316)
8. Esrig D, Freeman JA, Elmajian DA, et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol. 1996;156:1071-1076. (Pubitemid 26269831)
9. Njinou NB, Lorge F, Moulin P, et al. Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases. J Urol. 2003;169:149-152. (Pubitemid 35461575)
10. Herr HW, Donat SM. Prostatic tumor relapse in patients with superficial bladder tumors: 15-year outcome. J Urol. 1999;161:1854-1857. (Pubitemid 29420748)
11. Pagano F, Bassi P, Ferrante GL, et al. Is stage pT4a (D1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? a necessary distinction for contiguous or noncontiguous involvement. J Urol. 1996;155:244-247. (Pubitemid 126426473)
12. Shen SS, Lerner SP, Muezzinoglu B, et al. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol 2006;37:726-734. (Pubitemid 43956541)
13. Stöckle M, Meyenburg W, Wellek S, et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol. 1995;153:47-52. (Pubitemid 24379794)
14. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol. 1996;155:495-500. (Pubitemid 26023531)
15. Liedberg F, Chebil G, Månsson W. Urothelial carcinoma in the prostatic urethra and prostate: current controversies. Expert Rev Anticancer Ther 2007;7:383-390. (Pubitemid 46488342)
16. Trpkov K, Bartczak-McKay J, Yilmaz A. Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens. Am J Clin Pathol 2009;132:211-220.
17. Bhargava R, Beriwal S, McManus K, et al. CK5 is more sensitive than CK5/6 in identifying the "basal-like" phenotype of breast carcinoma. Am J Clin Pathol. 2008;130:724-730.
18. Higgins JP, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol 2007;31:673-680. (Pubitemid 46684205)
19. Bassily NH, Vallorosi CJ, Akdas G, et al. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma. Am J Clin Pathol. 2000;113:383-388. (Pubitemid 30217386)
20. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962-972.
21. Jiang J, Ulbright TM, Younger C, et al. Cytokeratin 7 and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis. Arch Pathol Lab Med. 2001;125:921-923. (Pubitemid 32623190)
22. McKenney JK, Desai S, Cohen C, et al. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001;25:1074-1078. (Pubitemid 32685906)
23. Mallofré C, Castillo M, Morente V, et al. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol. 2003;16:187-191. (Pubitemid 36337422)
24. Yildiz IZ, Recavarren R, Armah HB, et al. Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies. Diagn Pathol. 2009;4:35.
25. Ishii S, Ohbu M, Toomine Y, et al. Immunohistochemical, molecular, and clinicopathological analyses of urothelial carcinoma, micropapillary variant. Pathol Int 2011;61:723-730.
26. Genega EM, Hutchinson B, Reuter VE, et al. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod Pathol. 2000;13:1186-1191.
27. Kaufmann O, Fietze E, Mengs J, et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001;116:823-830. (Pubitemid 33108152)
28. Garcia FU, Haber MM, Chen X. Prostatic basal cells in the peripheral and transitional zones: zonal variation in morphology and in immunophenotype. Prostate. 2007;67:1686-1692. (Pubitemid 350036954)
29. Simon RA, di Sant'Agnese PA, Huang LS, et al. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol. 2009;40:252-258.
30. Qiu YQ, Leuschner I, Braun PM. Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review. Asian J Androl. 2008;10:855-863.
31. Sinha AA, Gleason DF, Wilson MJ, et al. Immunohistochemical localization of laminin in the basement membranes of normal, hyperplastic, and neoplastic human prostate. Prostate. 1989;15:299-313. (Pubitemid 20084717)
32. Chuang AY, DeMarzo AM, Veltri RW, et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol. 2007;31:1246-1255. (Pubitemid 47207130)